

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application:

1. (Currently Amended) A gel formulation for the transdermal or transmucosal administration of an active agent comprising:
 - a single active agent of testosterone which is present in an amount of about 1% or less by weight of the formulation;
 - a gelling agent present in an amount of about 1.2% by weight;
 - a delivery vehicle comprising ~~an alkanol~~ ethanol in an amount of about 47.5% by weight, ~~a polyalcohol~~ propylene glycol in an amount of 6% by weight and ~~a permeation enhancer of a monoalkyl ether of diethylene glycol~~ monoethyl ether of diethylene glycol in an amount of about 5% by weight, with the delivery vehicle present in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces; and
 - water;

wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation, and

~~wherein the alkanol is present in an amount between 5 to 80% by weight of the delivery vehicle, the polyalcohol is present in an amount between 1% to 15% by weight of the delivery vehicle, and the permeation enhancer is present in an amount between 0.2% to 15% by weight of the delivery vehicle, with the polyalcohol and permeation enhancer present in a weight ratio of 2:1 to 1:1 and the total amount of polyalcohol and permeation enhancer being not more than 15% of the formulation, so that the delivery vehicle facilitates absorption of the at least one active agent by the dermal or mucosal surfaces so that transfer or removal of the formulation from such surfaces is minimized.~~

Claim 2. (Cancelled)

3. (Previously Presented) The formulation of claim 1, wherein the alkanol is present in an amount between 20 to 65% of the formulation; the polyalcohol is propylene glycol; the permeation enhancer is diethylene glycol monoethyl ether; the gelling agent is present in an amount of between 0.05% to 4% of the formulation, and the formulation includes a neutralizing agent present in an amount between 0.05% and 1% of the formulation, and the water is present in an amount between 20% to 65% of the formulation.

4. (Previously Presented) The formulation of claim 3, which includes a sequestering agent.

5. (Previously Presented) The formulation of claim 1, wherein the alkanol is in combination with the water to form a hydroalcoholic mixture, the hydroalcoholic mixture is present in an amount of between 40 to 98% by weight of the delivery vehicle, and the alkanol is present in an amount of between 5% to 80% by weight of the mixture, and the water is present in an amount of between 20% to 95% by weight of the mixture.

6. (Canceled)

7. (Previously Presented) The formulation of claim 1, wherein the alkanol is a C₂ to C₄ alcohol selected from the group consisting of ethanol, isopropanol, and n-propanol, and the polyalcohol is propylene glycol or polypropylene glycol, and the permeation enhancer is diethylene glycol monoethyl ether.

Claims 8. to 10. (Cancelled)

11. (Previously Presented) The formulation of claim 1, which includes at least one of a neutralizing agent, buffering agent, moisturizing agent, humectant, surfactant, antioxidant, or emollient.

Claim 12. (Cancelled)

13. (Previously Presented) A method for treating hormonal disorders in a subject, the method comprising administering to a subject in need of such treatment the gel formulation of claim 1 for treating at least one symptom of the hormonal disorder selected from the group consisting of hypogonadism, female menopausal symptoms, female sexual dysfunction, hypoactive sexual desire disorder, and adrenal insufficiency, and wherein the administration of the formulation decreases the frequency of at least one clinical symptom of the hormonal disorder.

Claims 14. to 16. (Cancelled)

17. (Previously Presented) The method of claim 13, wherein the subject is a female subject, and the therapeutically effective dosage of testosterone is from about 2.2 milligrams to about 0.88 grams each 24 hours.

18. (Previously Presented) The method of claim 13, wherein the subject is a female subject, and further wherein the method increases serum levels of the testosterone to about 142 nanograms per deciliter.

19. (Previously Presented) The method of claim 13, wherein the subject is a female subject, and further wherein the method increases serum levels of the testosterone to about 17 picograms per milliliter.

Claims 20. to 28. (Canceled)

29. (Previously Presented) The method of claim 13, wherein a male subject is treated for hypogonadism.

Claims 30. to 36. (Cancelled)

37. (Currently Amended) A formulation for the transdermal or transmucosal administration of an active agent consisting essentially of:

a single active agent of testosterone which is present in an amount of about 1% or less by weight of the formulation;

a gelling agent;

a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer of a monoalkyl ether of diethylene glycol in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces; and

water;

wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation; and

wherein the alkanol is ethanol and is present in an amount between 5 to 80% by weight of the delivery vehicle, the polyalcohol is propylene glycol and is present in an amount between 1% to 15% by weight of the delivery vehicle, and the permeation enhancer is monoethyl ether of diethylene glycol and is present in an amount between 0.2% to 15% by weight of the delivery vehicle, with the polyalcohol and permeation enhancer present in a weight ratio of 2:1 to 1:1 and the total amount of polyalcohol and permeation enhancer being not more than 15% of the formulation, so that the delivery vehicle facilitates absorption of the at least one active agent by the dermal or mucosal surfaces so that transfer or removal of the formulation from such surfaces is minimized.

Claims 38 to 45. (Cancelled)

46. (Previously Presented) The formulation of claim 37, which includes at least one of a neutralizing agent, buffering agent, moisturizing agent, humectant, surfactant, antioxidant, or emollient.

Claims 47. to 55. (Cancelled)

56. (Previously Presented) A kit for treating a subject for increasing serum levels of a hormone in a subject comprising:

a gel formulation according to claim 1; and
a container that retains the formulation and includes a dispenser for releasing or applying a predetermined dosage or volume of the formulation upon demand.

57. (Original) The kit of claim 56, wherein the dispenser automatically releases the predetermined dosage or volume upon activation by a user.

58. (Original) The kit of claim 56, wherein the dispenser is a pump.

Claim 59. (Cancelled)

60. (Previously Presented) A formulation for the transdermal or transmucosal administration of an active agent for treating a hormonal disorder in a subject consisting of:

a single active agent of testosterone present in an amount of about 1% by weight of the formulation for treating at least one symptom of the hormonal disorder;

one or more of a gelling agent, a neutralizing agent, a sequestering agent, a buffering agent, a moisturizing agent, a humectant, a surfactant, an antioxidant, or an emollient; and

a delivery vehicle comprising an alkanol, propylene glycol, a permeation enhancer, and water in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces, wherein the alkanol is ethanol present in an amount between 20 to 65% by weight of the delivery vehicle, the propylene glycol is present in an amount between 1% to 15% by weight of the delivery vehicle, and the permeation enhancer is diethylene glycol monoethyl ether present in an amount between 0.2% to 15% by weight of the delivery vehicle, with the propylene glycol and permeation enhancer being present in a weight ratio of 2:1 to 1:1, and the total amount of polyalcohol and permeation enhancer being not more than 15% of the formulation, so that the delivery vehicle facilitates absorption of the at least one active agent by the dermal or mucosal surfaces; and

wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation and the delivery vehicle facilitates absorption of the at least one

active agent by the dermal or mucosal surfaces so that transfer or removal of the formulation from such surfaces is minimized.

61. (Previously Presented) A kit for treating a subject for increasing serum levels of an active agent in a subject comprising:
the formulation according to claim 60; and
a container that retains the formulation and includes a dispenser for releasing or applying a predetermined dosage or volume of the formulation upon demand.

62. (Previously Presented) The kit of claim 61, wherein the dispenser automatically releases the predetermined dosage or volume upon activation by a user.

63. (Previously Presented) The kit of claim 61, wherein the dispenser is a pump.

Claims 64. to 66. (Cancelled)

67. (Previously Presented) A method for treating hormonal disorders in a subject, the method comprising administering to a subject in need of such treatment the formulation of claim 37.

68. (Previously Presented) A method for treating hormonal disorders in a subject, the method comprising administering to a subject in need of such treatment the formulation of claim 60.

Claims 69. to 70. (Canceled)

71. (Previously Presented) The formulation of claim 37, wherein the testosterone is present in an amount of about 1% by weight, the gelling agent is present in an amount of about 1.2% by weight, the alkanol is ethanol in an amount of about 47.5% by weight, the polyalcohol is propylene glycol in an amount of 6% by weight, and the permeation enhancer is a monoethyl ether of diethylene glycol in an amount of about 5% by weight.

72. (Previously Presented) The formulation of claim 60, wherein the testosterone is present in an amount of about 1% by weight, the alkanol is ethanol in an amount of about 47.5% by weight, the polyalcohol is propylene glycol in an amount of 6% by weight, and the permeation enhancer is present in an amount of about 5% by weight.